RYTM News and Press, Rhythm Pharmaceuticals Inc. From 03/01/21

Rhythm Pharmaceuticals (RYTM): Q4 GAAP EPS of -$0.79.Cash, cash equivalents and short-term investments of $172.8M.Press Release For further details see: Rhythm Pharmaceuticals reports Q4 results

-- Received FDA approval of IMCIVREE™ (setmelanotide), the first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency -- -- Announced positive topline data from Phase 3 pivotal trial evaluating setmelanotide in Bardet-B...

Today, we take our first in-depth look at Rhythm Pharmaceuticals which is targeting severe obesity in rare diseases. The company has bolstered its coffers significantly in 2021 and has some approaching milestones. A full analysis on Rhythm Pharmaceuticals is provided in the paragr...

BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., President and Chief Executive ...

BOSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced the closing of its public offering of 5,750,000 shares ...

Rhythm Pharmaceuticals (RYTM) slips 3% premarket after pricing public offering of 5M common shares at $30.00/share.Underwriters' over-allotment is an additional 750K shares.Closing date is February 9. Morgan Stanley, BofA Securities, Cowen and Stifel are acting as the join...

Rhythm Pharma (RYTM) announced a proposed public offering of $150M of shares.The company also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5M of shares.Morgan Stanley, BofA Securities, Cowen and Stifel will act as the joint boo...

Gainers: [[RDHL]] +25.6%. [[GOGO]] +18.6%. [[BBBY]] +17.3%. [[RYTM]] +14.6%. [[AKRO]] +13.6%.Losers: [[OPCH]] -16.7%. [[GRTX]] -16.6%. [[TTOO]] -15.3%. [[WMG]] -7.7%. [[FFIV]] -7.5%. For further details see: BBBY, RDHL, TTOO and OPCH among after-hours movers

Stifel analyst Derek Archila raises price target for Rhythm (RYTM) from $36 to $67, a more than 86% increase.At current levels, he says shares are "very cheap."Archila cites "compelling data" from a Phase 2 basket trial of Imcivree (setmelanotide) for obesity as a catalyst.Trial results, rele...

Rhythm Pharmaceuticals (RYTM) announces positive data from multiple cohorts in its Phase 2 Basket Study evaluating setmelanotide for the treatment of severe obesity due to genetic variants in the melanocortin-4 receptor (MC4R) pathway.Clinical data from five cohorts totaling 65 patients demon...